Fight CRC Clinical Trial Finder
| NCT ID | Title | Phase | Date Added | Location | Prior IO Allowed | CRC-directed | Status | Drugs | Tags |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT05292417 |
TitleRadiotherapy in Combination With Sintilimab，GM-CSF and Fruquintinib in Patients With MSS mCRC | Phase
Phase 2
|
Date Added 2022-03-23 |
Location
China
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Fruquintinib, GM-CSF, Sintilimab |
Tags
MSS/ MMRp
|
| NCT ID NCT04687631 |
TitleConversion Therapy of RAS/BRAF Wild-Type Colorectal Cancer Patients With Initially Unresectable Liver Metastases | Phase
Phase 3
|
Date Added 2020-12-29 |
Location
China
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
mFOLFOXIRI Plus Bevacizumab, mFOLFOXIRI plus Cetuximab |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID LUMINESCENCE |
TitleIpilimumab, Maraviroc and Nivolumab (LUMINESCENCE) | Phase
Phase 1
|
Date Added 2019-01-25 |
Location |
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Ipilimumab, maraviroc, Nivolumab, Celsentri, Opdivo, Selzentry, Yervoy |
Tags
MSS/ MMRp
|
| NCT ID NCT04866862 |
TitleFruquitinib Combined With Camrelizumab in Non MSI-H/dMMR Refractory Colorectal Cancer | Phase
Phase 2
|
Date Added 2021-04-30 |
Location
China
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Combination of Fruquintinib and Camrelizumab |
Tags
MSS/ MMRp
|
| NCT ID NCT03835949 |
TitleStudy of TJ004309 in Combination With Atezolizumab (Tecentriq(R)) in Patients With Advanced or Metastatic Cancer | Phase
Phase 1
|
Date Added 2019-02-11 |
Location
Alabama, United States
Arizona, United States California, United States Texas, United States |
Prior IO Allowed No |
CRC-directed No |
Status
Active, not recruiting
|
Drugs
Atezolizumab, TJ004309 |
Tags
MSS/ MMRp
|
| NCT ID NCT04432857 |
TitleAN0025 and Pembrolizumab Combination in Advanced Solid Tumors | Phase
Phase 1
|
Date Added 2020-06-16 |
Location
Missouri, United States
Texas, United States Utah, United States Virginia, United States France |
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
AN0025, Pembrolizumab |
Tags
MSS/ MMRp
|
| NCT ID NCT03239145 |
TitlePembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor | Phase
Phase 1
|
Date Added 2017-08-03 |
Location
Massachusetts, United States
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
Pembrolizumab, Trebananib |
Tags
MSS/ MMRp
|
| NCT ID NCT03494946 |
TitleLiver Transplantation Compared to Chemotherapy in Patients With ColoRectal Cancer | Phase
Not Applicable
|
Date Added 2018-04-11 |
Location
Norway
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Chemotherapy |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03911557 |
TitleDurvalumab and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors | Phase
Phase 2
|
Date Added 2019-04-11 |
Location
Kentucky, United States
|
Prior IO Allowed No |
CRC-directed No |
Status
Active, not recruiting
|
Drugs
Durvalumab and Tremelimumab |
Tags
MSS/ MMRp
|
| NCT ID NCT03030378 |
TitlePembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors | Phase
Phase 1
|
Date Added 2017-01-25 |
Location
California, United States
Colorado, United States Connecticut, United States Florida, United States Georgia, United States Iowa, United States Maryland, United States Massachusetts, United States Missouri, United States New Jersey, United States North Carolina, United States Ohio, United States Pennsylvania, United States Texas, United States Virginia, United States |
Prior IO Allowed No |
CRC-directed No |
Status
Active, not recruiting
|
Drugs
Edodekin alfa, Pembrolizumab |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
